Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy […]
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy […]
